Lincoln Pharmaceuticals Limited (BOM:531633)

Market Cap	12.95B +15.5%
Revenue (ttm)	6.71B +13.0%
Net Income	878.94M +6.7%
EPS	43.88 +6.7%
Shares Out	20.03M
PE Ratio	14.73
Forward PE	n/a
Dividend	1.80 (0.28%)
Ex-Dividend Date	Sep 12, 2025

Volume	967
Open	648.85
Previous Close	650.80
Day's Range	642.55 - 651.45
52-Week Range	439.95 - 770.00
Beta	0.35
Analysts	Strong Buy
Price Target	322.00 (-50.19%)
Earnings Date	May 28, 2026

About Lincoln Pharmaceuticals

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics. It also exports its products to approximately 60 countries, including Europe, Canada, Latin and North America, Africa, the Asia Pacific, and South East As...

• Industry: Pharmaceutical Preparations
• Founded: 1979
• Employees: 1,853
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 531633

Financial Performance

In fiscal year 2026, Lincoln Pharmaceuticals's revenue was 7.04 billion, an increase of 13.04% compared to the previous year's 6.23 billion. Earnings were 878.94 million, an increase of 6.74%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 17, 2026

Data Sources Report a data error